Ipca Laboratories financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹2,788cr+20.8% on Q1 FY26
Net profit
₹424cr+82.2% on Q1 FY26
EBITDA margin
24.0%+6.0 pts on Q1 FY26
EPS
₹15.84+72.4% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue2,7882,309+20.8%
EBITDA670416+60.8%
EBITDA margin24.0%18.0%+6.0 pts
Profit before tax572331+73.1%
Net profit424233+82.2%
EPS₹15.84₹9.19+72.4%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹2,788 crNet profit₹424 crNet margin15.2%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
48,977————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1,0711,0719317671,581
1,4601,4601,4401,39573.3
7047041,3021,3881,458
50,070————
10,1269,6468,9407,7056,244
—+7.9%+16.0%+23.4%—
2,2321,9791,7261,321927
22.0%20.5%19.3%17.2%14.8%
1,8031,5601,328964665
1,3751,184785523479
13.6%12.3%8.8%6.8%7.7%
₹51.63₹44.98₹29.08₹21.57₹18.58
—+54.7%+34.8%+16.1%—
—1,1421,321945806
—−652−776−411−494
490490546533311
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

IPCALAB₹1,930.50

Ipca Laboratories Ltd.

· Pharma & Health
₹ CrorePeersTORNTPHARMALKEMJBCHEPHARMABBOTINDIAAJANTPHARMANTHEMGLAXOMEDANTAMcap ₹48,977 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————48,976.8
- Cash, Equiv & ST Investments1,581.2767.3930.61,070.51,070.5
+ Minority Interest73.31,394.81,439.81,460.31,460.3
+ Total Debt1,457.51,387.51,301.7703.9703.9
Enterprise Value————50,070.4
Revenue6,244.37,705.08,939.69,646.310,125.6
Growth %, YoY—+23.4+16.0+7.9—
EBITDA926.81,321.21,726.11,978.62,231.7
Margin %14.8417.1519.3120.5122.04
EBIT665.2963.91,328.31,560.41,802.8
Net Income479.0522.9785.21,183.81,375.2
Margin %7.676.798.7812.2713.58
EPS, Adj (current shares)18.5821.5729.0844.9851.63
Growth %, YoY—+16.1+34.8+54.7—
Cash from Operations805.8944.71,321.31,142.0—
Capital Expenditures-494.5-411.3-775.5-652.3—
Free Cash Flow311.3533.4545.8489.7489.7
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Ipca Laboratories financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Ipca Laboratories (NSE: IPCALAB) had a market capitalisation of ₹48,868 crore at the 29 October 2026 close (₹1,926.20 a share), a PE ratio of 37.3 on the last four quarters' profit and a price-to-book ratio of 6.06. In FY26 its consolidated net profit attributable to shareholders was ₹1,141 crore on revenue of ₹9,646 crore; in Q1 FY27 (April–June 2026) it was ₹402 crore, up 72.3% year on year. Its debt-to-equity ratio was 0.07 on 31 March 2026. Promoters held 44.72% of the shares on 30 September 2026.

Share price used
₹1,926.20 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026
Share price and live chart
₹1,926.20 · 29 Oct close

Ipca Laboratories at a glance · consolidated

Market cap
₹48,868 Crat ₹1,926.20 · 29 Oct close
PE ratio (last 4 quarters)
37.342.8 on FY26 profit
Price to book (PB)
6.06book value ₹317.85 a share
ROE (FY26)
15.2%+4.1 pts vs FY25ROCE 16.1%
Debt to equity
0.07net cash ₹494 Cr
Promoter holding
44.72%unchanged vs 30 Jun 202630 September 2026
Dividend yield
0.31%₹6 a share in 12 months
Net worth
₹8,064 Cr+16.1% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹490 Cr−10.3% vs FY25

Questions

What is the Ipca Laboratories PE ratio today?

Ipca Laboratories' PE ratio is 37.3 at the 29 October 2026 close (₹1,926.20 a share): a market capitalisation of ₹48,868 crore divided by consolidated net profit attributable to shareholders of ₹1,310 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹1,141 crore) it is 42.8.

What is the Ipca Laboratories PB ratio (price to book value)?

Ipca Laboratories' price-to-book (PB) ratio is 6.06 at the 29 October 2026 close: a market capitalisation of ₹48,868 crore divided by shareholders' equity (book value) of ₹8,064 crore on 31 March 2026. That is a book value of ₹317.85 per share against a share price of ₹1,926.20.

What is the Ipca Laboratories ROE and ROCE?

In FY26, Ipca Laboratories' return on equity (ROE) was 15.2% and its return on capital employed (ROCE) was 16.1%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 11.1% and ROCE 14.7%.

What is the Ipca Laboratories market cap?

Ipca Laboratories' market capitalisation was ₹48,868 crore at the 29 October 2026 close: 25.37 crore shares at ₹1,926.20 each.

Is Ipca Laboratories debt free?

No. Ipca Laboratories had borrowings of ₹704 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.07. Its cash and current investments were ₹1,198 crore, so it held net cash of ₹494 crore.

What is the Ipca Laboratories dividend in 2026 and its record date?

In 2026, Ipca Laboratories has declared one dividend: ₹6 with record date 7 August 2026.

What is the Ipca Laboratories debt to equity ratio?

Ipca Laboratories' debt-to-equity ratio was 0.07 on 31 March 2026: borrowings of ₹704 crore against total equity of ₹9,524 crore. A year earlier, on 31 March 2025, it was 0.16.

What is the Ipca Laboratories dividend yield?

Ipca Laboratories' dividend yield is 0.31% at the 29 October 2026 close: dividends of ₹6 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,926.20. They were ₹6 on 7 August 2026.

What is the Ipca Laboratories promoter holding?

Promoters held 44.72% of Ipca Laboratories on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

What is the Ipca Laboratories net worth?

Ipca Laboratories' net worth — shareholders' equity in its consolidated balance sheet — was ₹8,064 crore on 31 March 2026, up 16.1% from ₹6,948 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹48,868 crore at the 29 October 2026 close.

What is the Ipca Laboratories book value per share?

Ipca Laboratories' book value per share was ₹317.85 on 31 March 2026: shareholders' equity of ₹8,064 crore divided by the 25.37 crore shares in issue, up 16.1% from ₹273.88 a year earlier. The share price at the 29 October 2026 close was ₹1,926.20.

What are the Ipca Laboratories latest quarterly results?

Ipca Laboratories' latest results are for Q1 FY27 (April–June 2026), filed on 13 August 2026: consolidated net profit attributable to shareholders ₹402 crore, up 72.3% from ₹233 crore in Q1 FY26; revenue from operations ₹2,788 crore, up 20.8% year on year.

What is the Ipca Laboratories EPS?

Ipca Laboratories' basic earnings per share (EPS) were ₹44.98 in FY26, against ₹29.08 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹51.63.

What is the Ipca Laboratories free cash flow?

In FY26, Ipca Laboratories generated ₹1,142 crore of cash from operations and spent ₹652 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹490 crore. In FY25 it was ₹546 crore.

When are the Ipca Laboratories next results?

Ipca Laboratories will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, the date of the board meeting it has notified to the exchanges.

What is the Ipca Laboratories shareholding pattern?

On 30 September 2026, Ipca Laboratories' shares were held by promoters 44.72%, foreign portfolio investors (FII/FPI) 11.53%, domestic institutions (DII) 36.59% (including mutual funds at 31.07%) and retail and other non-institutional investors 7.15%. Over the year, FII holding was up 1.10 percentage points from 10.43% and DII holding was down 0.18 percentage points from 36.77%.

What is the Ipca Laboratories revenue and profit in FY26?

In FY26 (April 2025–March 2026), Ipca Laboratories' consolidated net profit attributable to shareholders was ₹1,141 crore, up 54.7% from ₹738 crore in FY25, on revenue from operations of ₹9,646 crore (up 7.9%). Over three years, from FY23, net profit was up 142.1%.

Ipca Laboratories vs Torrent Pharma: how do they compare?

In FY26, Ipca Laboratories earned net profit attributable to shareholders of ₹1,141 crore on revenue of ₹9,646 crore, against ₹2,163 crore on ₹13,980 crore for Torrent Pharma. Ipca Laboratories' operating margin was 16.2% (Torrent Pharma 24.6%) and its return on equity 15.2% (Torrent Pharma 27.1%). At the 29 October 2026 close, Ipca Laboratories' market capitalisation was ₹48,868 crore against ₹1,74,205 crore for Torrent Pharma, and its PE ratio on FY26 profit 42.8 against 80.5.

How does Ipca Laboratories compare with its peers?

On FY26 consolidated figures, against Torrent Pharma, Alkem Laboratories and J.B. Chemicals & Pharmaceuticals: Ipca Laboratories' operating margin of 16.2% is the lowest of the four (Torrent Pharma 24.6%, Alkem Laboratories 17.8%, J.B. Chemicals & Pharmaceuticals 22.3%; peer average 21.6%); its return on equity of 15.2% is the lowest of the four (Torrent Pharma 27.1%, Alkem Laboratories 17.8%, J.B. Chemicals & Pharmaceuticals 18.7%; peer average 21.2%); its revenue growth over three years of 15.6% a year is the highest of the four (Torrent Pharma 13.3% a year, Alkem Laboratories 8.3% a year, J.B. Chemicals & Pharmaceuticals 9.6% a year; peer average 10.4% a year).

Where do these Ipca Laboratories figures come from?

From Ipca Laboratories' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.